NCT02117622 - A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India | Biotech Hunter

Enrollment

1,056

Participants

Timeline

Start Date

July 24, 2015

Primary Completion Date

April 5, 2017

Study Completion Date

April 5, 2017

Conditions

DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Interventions

DRUG

insulin degludec

Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba® is decided in advance of this study

Trial Locations (38)

110076

Novo Nordisk Investigational Site, Delhi

110088

Novo Nordisk Investigational Site, New Delhi

160062

Novo Nordisk Investigational Site, Mohali

201301

Novo Nordisk Investigational Site, Noida

380007

Novo Nordisk Investigational Site, Ahmedabad

400053

Novo Nordisk Investigational Site, Mumbai

411001

Novo Nordisk Investigational Site, Pune

411040

Novo Nordisk Investigational Site, Pune

440010

Novo Nordisk Investigational Site, Nagpur

452010

Novo Nordisk Investigational Site, Indore

462037

Novo Nordisk Investigational Site, Bhopal

500001

Novo Nordisk Investigational Site, Hyderabad

500004

Novo Nordisk Investigational Site, Hyderabad

500072

Novo Nordisk Investigational Site, Hyderabad

520002

Novo Nordisk Investigational Site, Vijayawada

522001

Novo Nordisk Investigational Site, Guntur